Synthesis and evaluation of ۹۹mTc-DOTA-ARA-۲۹۰ as potential SPECT tracer for targeting cardiac ischemic region

سال انتشار: 1400
نوع سند: مقاله ژورنالی
زبان: انگلیسی
مشاهده: 237

فایل این مقاله در 12 صفحه با فرمت PDF قابل دریافت می باشد

استخراج به نرم افزارهای پژوهشی:

لینک ثابت به این مقاله:

شناسه ملی سند علمی:

JR_IJBMS-24-11_004

تاریخ نمایه سازی: 23 آبان 1400

چکیده مقاله:

Objective(s): Myocardial infarction caused by ischemia of heart tissue is the main reason for death worldwide; therefore, early detection can reduce mortality and treatment costs. Erythropoietin (EPO) has protection effects on ischemic tissue due to nonhematopoietic peptide (pHBSP; ARA-۲۹۰) which is derived from the B-subunit of EPO. Materials and Methods: We designed and synthesized a modified DOTA-(Lys-Dabcyl۶, Phe۷)-ARA-۲۹۰ using Fmoc solid-phase peptide synthesis strategies. To improve serum stability, Fmoc-Lys-(Dabcyl)-OH as lipophilic amino acid was synthesized along with Fmoc-Phe-OH which then were substituted with Arg۶ and Ala۷, respectively; they were then investigated for the ability to detect ischemic cardiac imaging. DOTA-(Lys-Dabcyl۶,Phe۷)-ARA-۲۹۰ was labeled with technetium ۹۹m, and its radiochemical purity (RCP), stability in the presence of human serum and, specific bind to hypoxic H۹c۲ cells were evaluated. In vivo studies for biodistribution and SPECT scintigraphy were checked in a normal and cardiac ischemia rat model. Results: Radiolabeling purity was obtained more than ۹۶% by ITLC, and in vitro stability of the radiopeptide up to ۶ hr was ۸۵%. The binding of ۹۹mTc-ARA-۲۹۰ to hypoxic cells was remarkably higher than normoxic cells (۳ times higher than normoxic cells at ۱ hr). Biodistribution and SPECT imaging on the cardiac ischemic model showed that radiopeptide considerably accumulated in the ischemic region (cardiac ischemic-to-lung rate = ۳.۶۵ ID/g % at ۰.۵ hr).Conclusion: The results of studies, in vitro  and in vivo, indicated that ۹۹mTc-DOTA-(Lys-Dabcyl۶,Phe۷)-ARA-۲۹۰ could be an appropriate candidate for early diagnosis of cardiac ischemia.

نویسندگان

Naser Mohtavinejad

Faculty of Pharmacy, Baqiyatallah University of Medical Sciences, Tehran, Iran

Maliheh Hajiramezanali

Department of Radiopharmacy, Faculty of Pharmacy, Tehran University of Medical Sciences, Tehran, Iran

Mehdi Mehdi Akhlaghi

Research Center for Nuclear Medicine, Tehran University of Medical Sciences, Tehran, Iran

Ahmad Bitarafan-Rajabi

Echocardiography Research Center, Rajaie Cardiovascular Medical and Research Center, Iran University of Medical Sciences, Tehran, Iran

Nazila Gholipour

Faculty of Pharmacy, Baqiyatallah University of Medical Sciences, Tehran, Iran

مراجع و منابع این مقاله:

لیست زیر مراجع و منابع استفاده شده در این مقاله را نمایش می دهد. این مراجع به صورت کاملا ماشینی و بر اساس هوش مصنوعی استخراج شده اند و لذا ممکن است دارای اشکالاتی باشند که به مرور زمان دقت استخراج این محتوا افزایش می یابد. مراجعی که مقالات مربوط به آنها در سیویلیکا نمایه شده و پیدا شده اند، به خود مقاله لینک شده اند :
  • Benjamin EJ, Virani SS, Callaway CW, Chamberlain AM, Chang AR, ...
  • Garg P, Morris P, Fazlanie AL, Vijayan S, Dancso B, ...
  • Uversky VN, Redwan EM. Erythropoietin and co: intrinsic structure and ...
  • Brines M, Grasso G, Fiordaliso F, Sfacteria A, Ghezzi P, ...
  • Anagnostou A, Lee ES, Kessimian N, Levinson R, Steiner M. ...
  • Brines M, Patel NS, Villa P, Brines C, Mennini T, ...
  • Collino M, Thiemermann C, Cerami A, Brines M. Flipping the ...
  • Byeon J, Lim YR, Kim HH, Suh JK. Structural identification ...
  • Joshi D, Abraham D, Shiwen X, Baker D, Tsui J. ...
  • Al Badarin FJ, Malhotra S. Diagnosis and prognosis of coronary ...
  • McAfee JG, Neumann RD. Radiolabeled peptides and other ligands for ...
  • Powell MF, Grey H, Gaeta F, Sette A, Colón S. ...
  • Dumont F, Bischoff P. Non-erythropoietic tissue-protective peptides derived from erythropoietin: ...
  • Sleep D, Cameron J, Evans LR. Albumin as a versatile ...
  • Lumachi F, Zucchetta P, Marzola MC, Boccagni P, Angelini F, ...
  • Rahmanian N, Hosseinimehr SJ, Khalaj A, Noaparast Z, Abedi SM, ...
  • Nadtoka O, Vretik L, Gavrylko T, Syromyatnikov V. The photochemical ...
  • Behrendt R, White P, Offer J. Advances in Fmoc solid‐phase ...
  • Mojarrad P, Zamani S, Seyedhamzeh M, Omoomi FD, Karimpourfard N, ...
  • Varshney R, Hazari PP, Uppal JK, Pal S, Stromberg R, ...
  • Rezazadeh F, Sadeghzadeh N, Abedi SM, Abediankenari S. ۹۹mTc labeled ...
  • Varshney R, Hazari PP, Tiwari AK, Mathur R, Kaushik A, ...
  • Jokar S, Behnammanesh H, Erfani M, Sharifzadeh M, Gholami M, ...
  • Fan Y, Lu M, Yu XA, He M, Zhang Y, ...
  • Wu D, Yotnda P. Induction and testing of hypoxia in ...
  • Ding M, Lei J, Han H, Li W, Qu Y, ...
  • Jiao H, Zhao X, Han J, Zhang J, Wang J. ...
  • Sunderland JJ, Christian PE. Quantitative PET/CT scanner performance characterization based ...
  • Chen ZY, Wang YX, Lin Y, Zhang JS, Yang F, ...
  • Fleming IN, Manavaki R, Blower PJ, West C, Williams KJ, ...
  • Strauss HW, Nunn A, Linder K. Nitroimidazoles for imaging hypoxic ...
  • Curtis KK, Wong WW, Ross HJ. Past approaches and future ...
  • Fosgerau K, Hoffmann T. Peptide therapeutics: current status and future ...
  • Hesse B, Lindhardt TB, Acampa W, Anagnostopoulos C, Ballinger J, ...
  • Ghotbi AA, Kjær A, Hasbak P. Comparison of PET rubidium‐۸۲ ...
  • Okarvi SM. Peptide‐based radiopharmaceuticals: Future tools for diagnostic imaging of ...
  • Yang C, Xu Z, Zhao Z, Li L, Zhao T, ...
  • Krijger GC, Claessens HA, Wolterbeek HT. On the separation of ...
  • Amin T, Infantino A, Barlow R, Hoehr C. Validating production ...
  • Fan Y, Lu M, Yu XA, He M, Zhang Y, ...
  • Mohtavinejad N, Amanlou M, Bitarafan-Rajabi A, Pormohammad A, Ardestani MS. ...
  • Meng X, Pei H, Lan C. Icariin exerts protective effect ...
  • Imamura R, Okumi M, Isaka Y, Ichimaru N, Moriyama T, ...
  • Kitamura H, Isaka Y, Takabatake Y, Imamura R, Suzuki C, ...
  • نمایش کامل مراجع